Posts by Sandra Ansanay-Alex
Genolier Innovation Hub
A new medical Innovation Hub will open in 2024 “This is not a real estate project to house the headquarters of companies, but rather a kind of hotel for companies that will come to experiment and present their innovations for 6 to 24 months. The goal is to reduce the latency between the time…
Read MoreHaya Therapeuthics closes US$ 5 Million seed extension
The Lausanne-based company will open a branch office in San Diego to continue its growth HAYA closes US$ 5 Million seed extension led by Humboldt Fund to advance the development of its anti-fibrotic lead program targeting Wisper, a cardiac long non-coding RNA. In May 2021, the company also announced the closing of a US$…
Read MoreINTERVIEW : Claude Clément, BioAlps President
🔺 Claude Clément is BioAlps President. According to him, multiculturality is why Switzerland🇨🇭 has become so successful in the field of life sciences.
Read MoreScience first, politics second
The “Stick to Science” petition aims to allow Swiss and British researchers to remain in Horizon Europe programme. The Stick to Science initiative has been set up by a coalition of 140 British universities and by the Polytechnic schools of Lausanne and Zurich (EPFL and EPFZ). They are calling for open and barrier-free collaboration…
Read MoreAn implant could cure paralysis
A new implant enables patients with a complete spinal cord injury to stand, walk and even swim Michel Roccati, an Italian patient suffering from complete paraplegia following a motorcycle accident, was able to walk again thanks to an implant placed against his spinal cord. Grégoire Courtine, neuroscientist and professor at the EPFL, and Jocelyne…
Read MoreCHF 1 billion for Vaud-based start-ups
2021 was a record fundraising year for Swiss startups, according to the Swiss Venture Capital Report 2022. The covid 19 pandemic did not slow down investments in Switzerland. And companies in the canton of Vaud have been particularly fortunate. Vaud’s young tech firms pulled in CHF 604.6 million in venture capital. An additional CHF…
Read MoreLa Source Launches H4
La Source opens an innovation platform dedicated to care and health in Vaud (Switzerland). The H4 “Hands-on Human Health Hub” was created to help start-ups in the life sciences sector overcome their early-stage difficulties. The project represents an investment of CHF 3 million over 5 years. Half will be financed by the State of…
Read MoreMerck acquires Geneva-based biopharmaceutical company Chord Therapeutics
Merck invests into Cadribine to try to cure rare neuroinflammatory diseases Chord Therapeutics (Chord), a clinical-stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, announced on 20 December 2021, that it has been acquired by the leading science and technology company Merck. The strategic acquisition enables Merck to expand its neurology pipeline to develop…
Read More